Rapid establishment of long-term culture-initiating cells of donor origin after nonmyeloablative allogeneic hematopoietic stem-cell transplantation, and significant prognostic impact of donor T-cell chimerism on stable engraftment and progression-free survival

被引:36
作者
Keil, F
Prinz, E
Moser, K
Mannhalter, C
Kalhs, P
Worel, N
Rabitsch, W
Schulenburg, A
Mitterbauer, M
Greinix, H
机构
[1] AKH Vienna, Innere Med Klin 1, Knochenmarktransplantat, Dept Internal Med 1, A-1090 Vienna, Austria
[2] Clin Inst Med & Chem Lab Diagnost, Vienna, Austria
[3] Univ Vienna, Dept Transfus Med, Vienna, Austria
关键词
D O I
10.1097/01.TP.0000071862.42835.76
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Nonmyeloablative allogeneic hematopoietic stem-cell transplantation (NST) allows establishment of donor hematopoiesis without eradication of recipient stem cells by chemoradiotherapy. Quantification of donor chimerism may predict graft failure and relapse. Methods. We quantified donor long-term culture-initiating cells (LTC-IC) in nine patients during the early phase after NST and lineage-specific donor cells of myeloid (CD33(+), CD34(+), granulocytes) and lymphoid lineage (CD3(+), CD4(+), CD8(+), CD56(+)) in 38 patients with a median follow-up of 40 weeks after NST. Conditioning therapy consisted of fludarabine 90 mg/m(2) followed by total body irradiation of 2 Gy. Results. Only rapid establishment of donor T-cell chimerism was essential for stable donor engraftment. Patients with less than 90% of donor T cells 4 weeks after NST had a significantly higher risk of relapse, graft rejection, or both (14 of 18 patients) than patients with donor T-cell chimerism of 90% and higher (3 of 20 patients). Although conditioning therapy was nonmyeloablative, a significant decrease of repopulating stem cells defined as LTC-IC was seen after 2 weeks followed by rapid recovery of LTC-IC to pretransplant values. Interestingly, all LTC-IC were from donor origin 2 and 4 weeks after NST, but rapid establishment of donor LTC-IC was not predictive for progression-free survival. Conclusions. Rapid establishment of lymphoid but not myeloid donor chimerism is a prognostic factor for stable donor engraftment after NST. It seems that an immunologic shield of alloreactive donor T cells is essential for early hematopoietic progenitors.
引用
收藏
页码:230 / 236
页数:7
相关论文
共 24 条
[11]   Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: Lack of residual donor hematopoiesis predicts aplasia [J].
Keil, F ;
Haas, OA ;
Fritsch, G ;
Kalhs, P ;
Lechner, K ;
Mannhalter, C ;
Reiter, E ;
Niederwieser, D ;
Hoecker, P ;
Greinix, HT .
BLOOD, 1997, 89 (09) :3113-3117
[12]   Ex vivo expansion of long-term culture initiating marrow cells by IL-10, SCF, and IL-3 [J].
Keil, F ;
Elahi, F ;
Greinix, HT ;
Fritsch, G ;
Louda, N ;
Petzer, AL ;
Prinz, E ;
Wagner, T ;
Kalhs, P ;
Lechner, K ;
Geissler, K .
TRANSFUSION, 2002, 42 (05) :581-587
[13]   Treatment of leukemic relapse after allogeneic stem cell transplantation with cytotoreductive chemotherapy and/or immunotherapy or second transplants [J].
Keil, F ;
Prinz, F ;
Kalhs, P ;
Lechner, K ;
Moser, K ;
Schwarzinger, I ;
Jäger, U ;
Fonatsch, C ;
Worel, N ;
Mannhalter, C ;
Rabitsch, W ;
Loidolt, H ;
Schulenburg, A ;
Mitterbauer, M ;
Höcker, P ;
Greinix, HT .
LEUKEMIA, 2001, 15 (03) :355-361
[14]   Hematopoietic donor chimerism and graft-versus-myeloma effect in relapse of multiple myeloma after allogeneic bone marrow transplantation [J].
Keil, F ;
Kalhs, P ;
Chen, X ;
Haas, OA ;
Fritsch, G ;
Chott, A ;
Lechner, K ;
Moser, K ;
Ackermann, J ;
Rabitsch, W ;
Worel, N ;
Mannhalter, C ;
Greinix, HT .
ANNALS OF HEMATOLOGY, 1999, 78 (08) :376-379
[15]   Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects [J].
McSweeney, PA ;
Niederwieser, D ;
Shizuru, JA ;
Sandmaier, BM ;
Molina, AJ ;
Maloney, DG ;
Chauncey, TR ;
Gooley, TA ;
Hegenbart, U ;
Nash, RA ;
Radich, J ;
Wagner, JL ;
Minor, S ;
Appelbaum, FR ;
Bensinger, WI ;
Bryant, E ;
Flowers, MED ;
Georges, GE ;
Grumet, FC ;
Kiem, HP ;
Torok-Storb, B ;
Yu, G ;
Blume, KG ;
Storb, RF .
BLOOD, 2001, 97 (11) :3390-3400
[16]  
Molina AJ, 2000, HDB BONE MARROW TRAN, P111
[17]  
RICE A, 1992, NOUV REV FR HEMATOL, V34, P167
[18]   Long-lasting decrease of marrow and circulating long-term culture initiating cells after allogeneic bone marrow transplant [J].
Selleri, C ;
Maciejewski, JP ;
De Rosa, G ;
Raiola, A ;
Risitano, AM ;
Picardi, M ;
Pezzullo, L ;
Luciano, L ;
Ricci, P ;
Varriale, G ;
Della Cioppa, P ;
Del Vecchio, L ;
Rotoli, B .
BONE MARROW TRANSPLANTATION, 1999, 23 (10) :1029-1037
[19]   Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation [J].
Storb, R ;
Yu, C ;
Wagner, JL ;
Deeg, HJ ;
Nash, RA ;
Kiem, HP ;
Leisenring, W ;
Shulman, H .
BLOOD, 1997, 89 (08) :3048-3054
[20]  
SUTHERLAND HJ, 1989, BLOOD, V74, P1563